Form 483

Emerald Supply Inc Form 483, 2026-04-16

FDA issued a Form 483 to Emerald Supply Inc on 2026-04-16 with 8 public-safe observations.

483· Form 483 issuedMedical Devices & Rad Health8 observations

Emerald Supply Inc · Brooklyn, United States · Issued April 16, 2026

Overview

  • 8 public-safe observations are available for this inspection.
  • 8 structured CFR citations are represented.
  • 1 investigator is tied to this Form 483.

Inspectional observations

Each observation cites the regulation FDA found the firm out of compliance with.

16 Apr 2026
21 CFR 803.17

Lack of Written MDR Procedures

Cited by Jacqueline S Warner

16 Apr 2026
21 CFR 820.20(e)

Quality System Procedures

Cited by Jacqueline S Warner

16 Apr 2026
21 CFR 820.35(a)

Records for complaints involving failure to meet specifications not maintained

Cited by Jacqueline S Warner

16 Apr 2026
21 CFR 820.50(a)(1)

Evaluation and Selection, Suppliers, Contractors, etc.

Cited by Jacqueline S Warner

16 Apr 2026
21 CFR 820.50(b)

Approval, inadequate purchasing data

Cited by Jacqueline S Warner

Inspected site

ESEmerald Supply IncBrooklyn, United States

Inspection team

Cited regulations

CFR citations associated with this Form 483.

CitationWhat it coversCited
21 CFR 803.17Cited across public-safe Form 483 observations1x
21 CFR 820.20(e)Cited across public-safe Form 483 observations1x
21 CFR 820.35(a)Cited across public-safe Form 483 observations1x
21 CFR 820.50(a)(1)Cited across public-safe Form 483 observations1x
21 CFR 820.50(b)Cited across public-safe Form 483 observations1x
ISO 13485:2016 Clause 4.2.1Cited across public-safe Form 483 observations1x
ISO 13485:2016 Clause 5.1Cited across public-safe Form 483 observations1x
ISO 13485:2016 Clause 7.1Cited across public-safe Form 483 observations1x

Full 483 report

Get the verbatim text of all 8 observations

The full inspection record, as Atlas holds it, so your team sees exactly what was cited and how it was answered.

  • The site's full inspection history around this Form 483
  • Whether these citations escalated to a warning letter
  • The investigators involved and the citations they repeat elsewhere